Figure 2.

Neutralization against Omicron sublineages BA.4/5, XBB.1.5, XBB.1.16, and EG.5.1. (A) Study design. (B–D) NT₅₀ values of 59 human sera against Omicron BA.4/5, XBB.1.5, XBB.1.16, and EG.5.1, collected after (B) 1 month (median 36 days), (C) 4 months (median 126 days) post-4th dose with parental ChAdOx1-S vaccine, and (D) 3 months (median 86 days) post-5th dose with bivalent mRNA vaccine. (E) Paired analysis of 1 and 4 months post 4th dose with parental ChAdOx1-S vaccine, and 3 months post 5th dose with bivalent mRNA vaccine serum neutralizing titers against D614G variant, Omicron BA.4/5, XBB.1.5, XBB.1.16, and EG.5.1 from 59 individuals. (B–D) Colors designate SARS-CoV-2 variants, data points represent individual subjects and dotted lines represent the lower limit of detection of NT₅₀ (LOD = 18). Geometric mean titers (GMTs) are noted above the respective groups. The fold of GMT reduction against each Omicron sublineage compared with the GMT against B.1.1.28 (SP-HIAE-ID02/2020) are noted above the respective GMTs. Groups were compared by Wilcoxon matched-pairs signed-rank test (ns = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). Panel (A) was created with BioRender.com (accessed on 10 November 2023) and panels (B–E) were generated using GraphPad Prism v10.0 software. See Tables S3 and S4 for complete data.